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Zusammenfassung 
Im Menschen basiert das hochaufgelöste Sehen auf einer spezialisierten anatomi-
schen Struktur der Netzhaut, der sogenannten Makula. Obwohl sie nur einen 
Durchmesser von 5,5 mm hat, ist die Makula unentbehrlich für Sehvorgänge bei 
denen ein Objekt fixiert wird, wie zum Beispiel beim Lesen oder dem Erkennen 
von Gesichtern. Ein Verlust der Makula führt daher bei Betroffenen zu starken 
Einschränkungen im Alltag, auch wenn das periphere Sehen erhalten ist und so 
zumindest eine räumliche Orientierung noch möglich ist.  
Makuladegeneration tritt für gewöhnlich entweder als multifaktorielle Alterser-
krankung (altersbedingte Makuladegeneration, AMD) oder aber als vererbte, sel-
tene Erkrankung auf (die häufigste ist dabei Morbus Stargardt, STGD1). AMD 
kann in eine „feuchte“ (exudative) Form und eine „trockene“ (nicht-exudative) 
Form unterteilt werden. Die feuchte Form ist charakterisiert durch die Neubildung 
von Blutgefäßen mit dadurch bedingter Ödembildung und Einblutungen, während 
die trockene Form durch eine örtliche Degeneration von Photorezeptoren, retina-
len Pigmentepithelzellen und des versorgenden Kapillarbetts gekennzeichnet ist. 
Der erbliche M. Stargardt hat ein ähnliches klinisches Bild wie die trockene AMD, 
obwohl die zugrundeliegenden Krankheitsmechanismen unterschiedlich sind. Bis-
lang sind sowohl AMD, als auch M. Stargardt nicht heilbar. Da die feuchte AMD 
aber von einen Überschuss an Wachstumsfaktoren, wie z. B. dem vascular endo-
thelial growth factor (VEGF), begleitet ist, erlaubt eine wiederholte intravitreale 
Gabe von anti-VEGF Therapeutika die akuten, durch das Ödem bedingten Sehstö-
rungen zu beseitigen und den Krankheitsverlauf zu verlangsamen.  
Die vorliegende Doktorarbeit beschäftigt sich mit den pathologischen Verände-
rungen und der pharmakologischen Therapie der Makuladegeneration und unter-
sucht dabei drei Aspekte:  
1) Licht- und elektronenmikroskopische Untersuchung der Pathomechanis-
men bei AMD und M. Stargardt anhand von menschlichem Spendermateri-
al bzw. von drei Stargardt Mausmodellen 
2) Aufklärung der subzellulären Ursprungs der Nahinfrarot-Autofluoreszenz 
(NIR-AF), die zur Diagnostik und Verlaufsbeobachtung bei retinalen Er-
krankungen wie AMD und M. Stargardt eingesetzt wird 
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3) Untersuchung der unerwünschte Arzneimittelwirkungen auf ultrastruktu-
reller Ebene nach der intravitrealen Gabe von anti-VEGF Wirkstoffen für 
die Behandlung der feuchten AMD 
Eine licht- und elektronenmikroskopische Untersuchung von menschlichem Au-
gengewebe mit und ohne AMD zeigte, dass sowohl in der trockenen, als auch der 
feuchten Form der AMD, der Verlust der Choriocapillaris, dem versorgenden Ka-
pillarbett, der retinalen Degeneration vorausgeht. Diese Studie beantwortete die 
lange unbeantwortete Frage welches retinale Gewebe bei der AMD zuerst degene-
riert. Der Verlauf von M. Stargardt wurde mit Hilfe von 3 häufig verwendeten 
Stargardt Mausmodellen untersucht. Diese Untersuchung zeigte auffällige patho-
logische Veränderungen, die aber nur in einem albino und nicht in zwei pigmen-
tierten Mausmodellen auftraten. Dies unterstreicht den vorteilhaften Einfluss, den 
okulares Melanin womöglich auf die Krankheitsausprägung hat.  
Weiterhin konnte gezeigt werden, dass NIR-AF keine intrinsische Eigenschaft von 
Melanin ist, wie bislang angenommen wurde, sondern vielmehr eine Konsequenz 
von Melaninschädigung aufgrund von Licht und/oder oxidativem Stress. Weiter-
hin stellte sich heraus, dass NIR-AF nicht nur von Melanosomen, sondern auch 
von Lipofuszin, einem Nebenprodukt des Sehzyklus, das sich im Alter oder bei 
bestimmten Krankheiten im retinalen Pigmentepithel ansammelt, herrühren 
kann. Diese Erkenntnisse sind sowohl für die Aufklärung der Pathomechanismen 
bei Melanin- und Lipofuszin-assoziierten Krankheiten, als auch für die Verbesse-
rung der NIR-AF basierten Diagnostik relevant.  
Darüber hinaus legten frühere ultrastrukturelle Untersuchungen von unerwünsch-
ten Arzneimittelwirkungen des Immunglobulin G (IgG)-basierten anti-VEGF 
Wirkstoffes Bevacizumab nahe, dass das IgG-Fc Fragment (engl. fragment 
crystallisable) an der Entstehung der beobachteten unerwünschten Wirkungen 
beteiligt ist. Dies wurde anhand von Studien bestätigt, bei denen ultrastrukturelle 
Veränderungen nach intravitrealer Gabe von anti-VEGF Wirkstoffen mit und ohne 
Fc Fragment in Affenaugen bzw. nach intravitrealer Gabe von isoliertem Fc Frag-
ment in Rattenaugen untersucht wurden. Diese Arbeiten unterstreichen die Rolle 
des Fc Fragments bei unerwünschten Arzneimittelwirkungen von IgG-basierten 
pharmakologischen Wirkstoffen, die in der Augenheilkunde Anwendung finden.  
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Zusammengefasst untersucht die vorliegende Doktorarbeit Schlüsselereignisse im 
Pathomechanismus der AMD (Reihenfolge des Gewebeverlustes) und des M. Star-
gardt (angedeutete Schutzwirkung des Melanins), klärt die subzelluläre Herkunft 
des NIR-AF Signals auf, das für augenheilkundliche Diagnostik und Verlaufsbe-
obachtung herangezogen wird, und bestätigt die Beteiligung des Fc Fragments an 
unerwünschten Arzneimittelwirkungen, die nach der intravitrealen Gabe von anti-
VEGF Wirkstoffen beobachtet wurden.  
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Summary  
In humans, high-resolution vision relies on a specialised anatomical structure of 
the retina, the so called macula. While only 5.5 mm in diameter, the macula is in-
dispensable for visual tasks depending on visual fixation of an object, such as read-
ing and facial recognition. Loss of the macula therefore heavily impairs affected 
individuals, even though peripheral vision is not inhibited and spatial orientation 
is still possible.  
Macular degeneration usually arises either as multifactorial age-dependent disease 
(age-related macular degeneration, AMD) or as rare hereditary disease (the most 
common one being Stargardt disease, STGD1). AMD can be sub-classified in a 
“wet” (exudative) form that is characterised by neovascularisation with collateral 
oedema and bleeding, and a “dry” (non-exudative) form defined by local degenera-
tion of photoreceptors, retinal pigment epithelium cells and the supporting capil-
lary bed. Inherited Stargardt disease has a similar clinical presentation to dry 
AMD, even though the underlying disease mechanisms differ. To date, no cure for 
AMD or Stargardt disease is available. However, since wet AMD is accompanied 
with a surplus of growth factors, e.g. vascular endothelial growth factor (VEGF), 
the repeated intravitreal application of anti-VEGF therapeutics allows for a rever-
sal of acute visual distortions due to oedema and a reduction of disease progres-
sion.  
This thesis deals with the pathologic processes and pharmacological therapy of 
macular degeneration and therefore investigates three aspects:  
1) pathomechanisms in AMD and Stargardt disease, investigated by light- and 
electron microscopy on human donor samples and three Stargardt mouse 
models, respectively  
2) resolving the subcellular origin of near-infrared autofluorescence (NIR-AF) 
used in diagnostics and monitoring of retinal diseases, such as AMD and 
STGD1 
3) adverse events on the ultrastructural level after intravitreal use of anti-
VEGF compounds for treatment of wet AMD 
A light and electron microscopic investigation of human ocular tissue with and 
without AMD revealed that a loss of choriocapillaris, the nourishing capillary bed 
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underneath the retina, precedes retinal degeneration in both the wet and the dry 
form of AMD. This study answered the open question of which retinal tissue is the 
first to degenerate in AMD. Stargardt disease progression was investigated in three 
commonly used Stargardt mouse models and revealed distinctive pathologic 
changes only present in an albino, but not in two pigmented mouse models, high-
lighting the potential beneficial impact of ocular melanin in disease modulation. 
NIR-AF was shown to not be an intrinsic property of melanin, as previously 
thought, but rather a consequence of melanin damage due to photic and/or oxida-
tive stress. Furthermore, NIR-AF was found to not only stem from melanosomes, 
but also partly from lipofuscin, a byproduct of the visual cycle that accumulates 
with age and/or disease in the retinal pigment epithelium. These findings are rele-
vant for both elucidating the pathomechanisms in melanin- and lipofuscin-
associated retinal diseases and the refinement of NIR-AF based diagnostics.  
And lastly, previous ultrastructural investigations of adverse events of the immu-
noglobulin G (IgG)-based anti-VEGF compound bevacizumab suggested that the 
fragment crystallisable (Fc) unit is involved in the development of said adverse 
events. This was confirmed by studies analysing ultrastructural changes after in-
travitreal application of anti-VEGF compounds with and without Fc fragment in 
monkey eyes and intravitreal application of isolated Fc fragments in rat eyes. 
These works emphasize the role of the Fc fragment in adverse events of IgG-based 
pharmacological compounds used in ophthalmology. 
To conclude, the present thesis investigates key events in the pathomechanisms of 
AMD (order of tissue loss) and STGD1 (indicated protective role of melanin), iden-
tifies the subcellular origin of the NIR-AF signal used in ophthalmologic diagnos-
tics and disease monitoring and confirms the involvement of the Fc fragment in 
adverse events observed after intravitreal application of anti-VEGF compounds. 
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1 Introduction 
1.1 Ocular anatomy 
The mammalian eyeball is enclosed by a three-layered wall consisting of the exte-
rior fibrous tunic (subdivided into cornea and sclera), the uvea in the middle (con-
sisting of choroid, ciliary body, iris) and the retina, the innermost layer (Fig. 1). 
The space inside the eyeball between lens and retina is filled by a clear, gelatinous 
mass called vitreous body.  
 
Figure 1: Schematic view of the primate eye (not to scale). Own work. 
The retina is a highly organised nervous tissue consisting of light-sensitive photo-
receptor cells, bipolar, horizontal and amacrine cells that are the first processing 
unit for the visual signal, Müller glia that are essential for structural integrity and 
light transmission and ganglion cells that transmit the visual signal towards the 
brain (Fig. 2). The big vessels of the retinal vasculature can be found in the inner-
most layers, the nerve fibre layer and the ganglion cell layer, while retinal capillar-
ies can be found above and below the inner nuclear layer.  
There are two types of photoreceptors: rod cells that function in low-light condi-
tions and mediate night vision and cone cells that function in bright-light condi-
tions and are responsible for colour vision. Both photoreceptor types are not 
equally distributed in the human retina. While rods are mostly present in the pe-
ripheral part of the retina, cones are predominantly found in the central parts. An 
outstanding anatomic feature of the primate central retina, that also has the high-
est density of cones, is the macula that will be described below in section 1.3.  
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A specialised subunit of the photoreceptor cell, the so-called outer segment, con-
tains 1000 – 2000 stacked discs. In rod cells, these discs are separate and not 
connected to the plasma membrane, while in cone cells, the discs are continuous 
invaginations of the plasma membrane. In the disc membranes, the visual pig-
ments, the most well-known being rhodopsin in rods, and further auxiliary pro-
teins are located. 
 
Figure 2: Schematic view of the human retina and underlying structures (not to scale). Own work, 
partially based on data published in [7]. 
The photoreceptors and the underlying retinal pigment epithelium (RPE) form a 
functional unit (reviewed in [8]). The main functions of the RPE comprise: 
- The visual cycle, the “recycling” of all-trans-retinal released by the photore-
ceptors after photo transduction to 11-cis-retinal that can be reused to form 
new visual pigments (reviewed in [9]). 
- Formation of the outer blood-retina barrier while transporting water and 
lactate from the retina to the blood and nutrients like glucose and do-
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cosahexaenoic acid from the blood to the retina. In fact, recent findings in-
dicate that RPE and photoreceptors share a “metabolic ecosystem” in which 
the RPE transports glucose to the photoreceptors that convert it to lactate 
by glycolysis; the lactate is then partly used by Müller cells and the RPE as 
fuel [10].  
- Phagocytosis of photoreceptor outer segment tips that are shed as part of 
the continual renewal of the outer segment. Since photoreceptor outer seg-
ments contain high levels of photosensitive material like polyunsaturated 
fatty acids and are exposed to intense light levels each day, photo-damaged 
material can accumulate. Thus, outer segment tips are shed each morning 
after light onset and phagocytosed by the RPE, while the outer segment is 
replenished at its base (reviewed in [11]). A complete renewal of the outer 
segment is thereby achieved within 10 days [12]. Since each adult human 
RPE cell covers about 35 photoreceptors, it is estimated that each RPE cell 
phagocytoses hundreds of thousands outer segment discs during its lifetime 
[11]. 
- Secretion of a variety of growth factors such as fibroblast growth factors, 
pigment epithelium-derived factor, ciliary neurotrophic factor, platelet-
derived growth factor, vascular endothelial growth factor, tissue inhibitor 
matrix protease, complement factor H, interleukin 8 and monocyte chemo-
tactic protein 1 among others. These factors are closely regulated in the 
healthy eye to ensure the stability of the photoreceptors, the stability of the 
supplying capillary bed (the so-called choriocapillaris, see below) and the 
immune modulation.  
The RPE forms a cuboidal monolayer and gained its name “pigment epithelium” 
from the fact that the RPE cells are highly pigmented. An overview over the RPE 
pigmentation will be given in section 1.2.  
The RPE is situated on Bruch’s membrane, which is not a membrane in the molec-
ular biological sense, but in the histological sense; it is composed of 5 distinct lay-
ers of extracellular matrix material as illustrated in Fig. 3: 1) the basement mem-
brane of the RPE, 2) the inner collagenous zone, 3) the central band of elastic fi-
bres, 4) the outer collagenous zone and 5) the basement membrane of the endo-
thelial cells of the choriocapillaris. With age, undegradable material beneath the 
RPE can accumulate either between the plasma membrane and the basement 
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membrane of the RPE (basal laminar deposits) or between the basement mem-
brane of the RPE and the inner collagenous zone (basal linear deposits) [13]. The 
latter type of deposit can form so-called drusen that are big enough to be observa-
ble by funduscopy and, when being large or present in high numbers, can be asso-
ciated with age-related retinal disease, as will be expanded on in section 1.4.1 [13, 
14]. 
 
Figure 3: Schematic view of the choriocapillaris/RPE/photoreceptor-interface (not to scale). RPE 
cells contain melanin (black), lipofuscin (yellow-orange) and melanolipofuscin (yellow-orange with 
black core) granules in the apical part of the cytoplasm. Microvilli contain elongated spindle-shaped 
melanin granules. Bruch’s membrane consists of five distinct layers (for details, please refer to the 
main text). Fenestration of choriocapillaris predominantly exists on the RPE-side of the vessels 
(arrowheads). Own work. 
Directly beneath Bruch’s membrane, the choriocapillaris, a capillary bed, is locat-
ed. The choriocapillaris supplies approximately 50% of the needed oxygen during 
dark adaption [15]. To facilitate this, the blood flow rate in the choriocapillaris is 
remarkably high and the vessels are fenestrated (Fig. 3). Since the retina is one of 
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the most metabolically active tissues in the human body with a high oxygen con-
sumption, a generous supply of oxygen and nutrients from the choriocapillaris al-
lows for a less dense retinal vasculature hence reducing light scattering effects by 
retinal blood vessels.  
Photoreceptors, RPE, Bruch’s membrane and choriocapillaris share a mutualistic 
relationship: impairment/loss of one structure leads to impairment/loss of the 
other structures [16]. The choriocapillaris marks the beginning of the choroid that 
consists of connective tissue, blood vessels and melanocytes with melanosomes. 
The melanin in the melanocytes is assumed to have two main functions: reducing 
uncontrolled scattered light that might result in disrupted perception and acting as 
an antioxidant, since the choroid is highly perfused due to the high oxygen need of 
the retina. However, in many vertebrates, part of the choroidal pigmentation is 
missing and replaced by a special structure named tapetum lucidum, which re-
flects light in a controlled manner and supports superior night vision in these spe-
cies (reviewed in [17]).  
1.2 Pigmentation of the retinal pigment epithelium 
The RPE differs from all other pigmented cells in its embryonic origin: while mel-
anocytes (including the melanocytes of the choroid) are derived from the neural 
crest, the RPE is derived from the neural ectoderm [18]. 
Most melanised tissues, such as hair and skin, express tyrosinase, the canonical 
key enzyme of melanogenesis, over the entire lifespan and therefore can continu-
ously synthesise melanin. In the RPE however, tyrosinase-expression was only 
found pre-natal (reviewed in [19]) and thus, according to established scientific 
doctrine, there is no melanin biosynthesis in the RPE after birth [20-22]. Howev-
er, post-natal melanin biosynthesis has been described in several species [19, 23-
26] and tyrosinase-independent melanin biosynthesis in RPE cells was seen in 
vitro [27]. 
RPE melanosomes are located both within the cell body and within the microvilli 
that encircle the photoreceptor outer segments (Fig. 3). Melanosomes can be spin-
dle-shaped (in microvilli, cell body) or spherical (only in cell body). The amount of 
melanin in the RPE in humans is independent of race [28]. In the past, it was as-
sumed that human RPE melanin exclusively consists of the dark-brown/black 
eumelanin, but at least for Caucasian donors it was shown that RPE melanin also 
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contains small amounts of pheomelanin, a red-coloured melanin type [29]. Ocular 
melanin has a variety of functions, including scavenging of extra light and reactive 
oxygen species [18, 22, 30], and its anti-oxidative properties are well documented 
[31-34]. However, once melanin ages, its former anti-oxidative character switches 
to pro-oxidative [35-37]. 
 
Figure 4: Scheme of proposed bisretinoid synthesis in the photoreceptor disc. All-trans-retinal (at-
RAL, light blue) is released from opsin (green) into the disc membrane of the photoreceptor. atRAL 
can either go to the cytoplasmic leaflet, where it is reduced by retinol dehydrogenase 8 (RDH8, 
magenta) to all-trans-retinol (atROL, orange) or it can go to the luminal leaflet where it binds to 
phosphatidylethanolamine (purple) forming N-retinylidene-phosphatidylethanolamine (NretPE) via 
Schiff-base formation. In the presence of functioning ATP-binding cassette A4 (ABCA4, cyan), 
NretPE is flipped to the cytoplasmic leaflet and atRAL can dissociate and is reduced by RDH8 to 
atROL. When no functioning ABCA4 is present, NretPE accumulates and can spontaneously react 
with atRAL to form a bisretinoid precursor molecule (dark blue). Modified from [38].  
During life, an additional pigment, the so-called age-pigment lipofuscin accumu-
lates within the RPE. In general, lipofuscin is considered to be a complex mixture 
of undegradable proteins and lipids that accumulates within the lysosomes of 
post-mitotic cells such as heart muscle cells and neurons [39]. It is characterised 
by its yellow-brown colour and a typical golden-orange autofluorescence. Howev-
er, RPE lipofuscin was shown to contain only minimal amounts of protein and in-
stead consisting mostly of lipids [40]. The major lipid components are bisretin-
oids, a family of undegradable molecules derived from retinal, emerging from side-
reactions of the visual cycle in the outer segment discs [41] (Fig. 4). The newly 
formed bisretinoids reach the RPE by the daily occurring phagocytosis of shed 
outer segment tips. An essential role in the formation of bisretinoids plays the en-
zyme ATP-binding cassette A4 (ABCA4), a flippase located in the rims of photore-
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ceptor outer segments discs. The role of this protein in inherited retinal disease 
will be discussed in section 1.4.2.  
Apart from the universally accepted mechanism illustrated in Fig. 4, other path-
ways of lipofuscin biosynthesis have been proposed: A 2012 study found that 
Abca4-/- mice reared in total darkness accumulate levels of bisretinoids similar to 
those in Abca4-/- mice reared in cyclic light, suggesting that lipofuscin is also de-
rived from free 11-cis-retinal [42]. Furthermore, a recent study found that ABCA4 
is also located in the lysosomal compartment of the RPE [43]. Interestingly, mice 
expressing ABCA4 in the RPE but not in the photoreceptors (RPE-Abca4-
Tg/Abca4−/− mice) have lower levels of bisretinoids and RPE autofluorescence 
than littermates expressing no ABCA4 at all [43], suggesting that RPE-localised 
ABCA4 is also involved in lipofuscin formation, but the mechanism still has to be 
elucidated.  
Lipofuscin is often considered to be a cytotoxic compound since lipofuscin can in-
hibit photoreceptor phagocytosis [44] and cause photo-oxidative damage [45]. 
RPE lipofuscin can also fuse to melanin, creating a melanolipofuscin granule con-
sisting of a melanin core and a lipofuscin shell. Analytical electron microscopy and 
nano-secondary ion mass spectrometry analyses of human RPE pigments con-
firmed that the elemental composition of melanin and melanin in melano-
lipofuscin, as well as of lipofuscin and lipofuscin in melanolipofuscin, are extreme-
ly similar, respectively [46, 47]. However, the melanin in melanolipofuscin has 
significantly elevated phosphorus levels (usually considered to be a marker for li-
pid content) compared to melanosomes, while the lipofuscin in melanolipofuscin 
has significantly elevated nitrogen levels (usually considered to be a marker for 
protein content) compared to lipofuscin granules [46, 47]. A2E (N-retinylidene-N-
retinylethanolamin), the best studied bisretinoid compound of lipofuscin, has de-
tergent-like effects on biomembranes [48, 49], disturbs the mitochondrial ATP-
synthesis [50], reduces lysosomal activity in the RPE [51, 52], and has pro-
apoptotic [53] as well as pro-angiogenic [54, 55] properties. After illumination of 
A2E-laden cells with blue light, DNA damage [56], changed expression of genes 
related to stress and immune response as well as apoptosis [57], and finally cell 
death [58-60] were documented. While noxious characteristics of lipofuscin and 
its constituent A2E have been extensively described [44, 45, 48-60], lipofuscin 
autofluorescence topography does not correlate to age-related photoreceptor loss 
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in the human [61]. Therefore, the relevancy of lipofuscin and melanolipofuscin for 
the development of age-related changes in the retina has recently been debated. 
RPE pigments are increasingly used as a marker for the state of the RPE in medi-
cal patient care by monitoring pigment autofluorescence (AF) in the back of the 
eye (fundus autofluorescence). Lipofuscin can be excited with short-wavelength 
light (SW; excitation wavelength: 488 nm, emission wavelength: > 500 nm) [62], 
while near infrared (NIR)-AF is thought to present melanin (excitation wave-
length: 787 nm, emission wavelength: > 800 nm) [63, 64]. SW-AF is routinely 
used not only to monitor the accumulation and distribution of lipofuscin in the 
RPE, but also as a substitute marker for the whole RPE. Thereby, SW-AF finds use 
in a broad spectrum of retinal disorders to judge the state of RPE, including but 
not limited to drug toxicity, tissue defects as well as inherited and acquired retinal 
dystrophies [65]. NIR-AF as a marker for melanin is a relatively new modality and 
while it has been established that not only RPE melanin, but also choroidal mela-
nin can add to the signal, the exact ratio, as well as other potential contributors to 
the signal are still under discussion [66]. Nevertheless, NIR-AF has proven to 
show characteristic changes in a variety of retinal diseases that oftentimes precede 
changes in SW-AF patterns [67-72]. Two of these diseases, namely age-related 
macular degeneration and Stargardt disease, are in the focus of this thesis and will 
be introduced in section 1.4. The question whether NIR-AF is in fact only derived 
from melanin will be answered in section 3.2. 
1.3 High-resolution central vision in the primate — the macula 
A histologically distinct area of the primate retina that is not present in the eyes of 
other mammals is the macula (reviewed in [73]). It has its name from the high 
concentration of the carotenoids lutein, zeaxanthin and meso-zeaxanthin which 
give this area a yellowish colour; thus the name “yellow spot” or in Latin macula 
lutea.  
In the macula’s centre, the inner neuroretinal layers up to the outer plexiform lay-
er are radially displaced, resulting in the formation of a pit (Fig. 5). The bottom of 
the pit, the foveola, is made up of densely packed cones and Müller cells and is the 
region of high-resolution central colour vision. Outer and inner segments are 
elongated in the foveola and the resulting curve is referred to as foveola externa. 
The foveola is surrounded by the fovea that contains the foveal slope which en-
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compasses all retinal layers. In this area, the ganglion and outer plexiform layers 
are very thick and the first rods appear. The fovea is enclosed by the parafovea 
with the thickest ganglion cell layer and increasing numbers of rods. The outer-
most area of the macula is the perifovea in which the ganglion cell layer decreases 
to a thickness of one cell layer and where rods outnumber cones.  
 
Figure 5: Schematic view of the primate macula (not to scale). Top: Schematic view of the fundus 
of a right eye. The centre of the anatomic macula comprises the perifovea, parafovea, fovea and 
foveola that are organised in concentric circles. The foveola is located approximately 4 mm tem-
poral from the centre of the optic disc, the point where ganglion cell axons leave the eye and start 
forming the optic nerve. The superior and inferior temporal branches of the central retinal artery 
and vein surround the macula. Bottom: Schematic transversal view of the macula with approximate 
dimensions. GCL: ganglion cell layer, IPL: inner plexiform layer, INL: inner nuclear layer, OPL: 
outer plexiform layer, ONL: outer nuclear layer, IS: inner segments, OS: outer segments, RPE: 
retinal pigment epithelium. Own work based on data published in [73]. 
By the radial displacement of overlaying cell layers, any light scattering effects of 
these cell portions are prevented. Not only the organization of the retinal layers is 
shifted in the macula, but also the retinal vasculature is diminished; only capillar-
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ies can be found in the macula, while the big retinal vessels surround the macula 
(Fig. 5). The fovea however, is completely avascular (foveal avascular zone), mak-
ing the foveal cells fully dependent on the choriocapillaris for oxygen and nutrition 
supply.  
The diminishment of potential light scattering elements in combination with the 
high density of cones and a low ratio of cones to ganglion cells (which means that 
signals from several cones do not converge to one ganglion cell, but rather each 
cone is connected to two to three ganglion cells [74]) allows the achievement of 
high visual acuity.  
The human macula has a diameter of about 5.5 mm, while the foveola has a diam-
eter of about 0.35 mm. Although very small in size, this tissue is crucial for every-
day visual tasks relying on high-resolution and high-acuity, such as reading and 
face recognition. This is also reflected in the fact that the fovea occupies only 
0.02% of the total retinal area, while it contains 25% of ganglion cells [73]. If the 
macula is damaged, central vision is heavily impaired. A group of diseases that 
damage the macula are summarised under the term macular degeneration. 
1.4 Macular degeneration 
Macular degeneration is an umbrella term that comprises several different diseas-
es with different aetiology. The most common one is the acquired age-related 
macular degeneration (AMD), a multifactorial disease that is the major cause for 
legal blindness in the elderly in industrialised nations [75]. Much rarer are the in-
herited juvenile macular degenerations that are associated with mutations in cer-
tain genes and typically present during childhood, such as Stargardt disease, X-
linked juvenile retinoschisis, and Best vitelliform macular dystrophy [76]. Other 
causes for macular degeneration are for instance pathologic myopia [77], drug tox-
icity [78] and presumed ocular histoplasmosis syndrome [79]. 
Since AMD and the subtype 1 of Stargardt disease (STGD1) share certain charac-
teristics, both diseases are in the focus of this thesis. An examination of the disease 
progression in both AMD and STGD1 will be performed in section 3.1. 
1.4.1 Age-related macular degeneration (AMD) 
AMD has a global prevalence of 8.7% in individuals aged 45 to 85 years [80]. It is 
estimated that in the year 2040 288 million people will be affected [80]. There are 
INTRODUCTION 
18 
several risk factors for the development and progression for AMD being discussed. 
A 2010 meta-analysis suggested that advanced age, smoking, previous cataract 
surgery and a familial history of AMD are strong and consistent risk factors for 
AMD, while a high body mass index, a history of cardiovascular disease, hyperten-
sion and plasma fibrinogen were identified as moderate risk factors [81]. However, 
a randomised clinical trial found no link between cataract surgery and the progres-
sion from early to advanced AMD [82]. On the other hand, a prospective popula-
tion-based cohort study found that a diet with high amounts of vegetables, fruit 
and fish significantly reduces the risk of developing AMD [83]. Genes involved in 
predisposition to AMD encode for proteins involved in the complement system 
(e.g. CFH, C3, CFI, C2/CFB), cholesterol and fat metabolism (e.g. APOE, CETP, 
LIPC), extracellular matrix (e.g. TIMP3) and yet unknown functions (ARMS2, 
HTRA1) [84-87].  
AMD can be divided into an early, an intermediate and a late stage (Fig. 6, re-
viewed in [75]). In early AMD, the characteristic hallmark is the formation of me-
dium-sized drusen, extensive basal linear deposits beneath the RPE, in both eyes 
(section 1.1). However, few small drusen in a single eye are not considered to be 
AMD, since drusen formation in itself is considered to be a part of normal aging 
[14]. Intermediate AMD is defined by the presence of at least one large druse and 
several medium sized drusen [75]. Late stage AMD can have two distinctive forms, 
either dry (non-neovascular, non-exudative) or wet (neovascular, exudative). Dry 
AMD is characterised by a local degeneration of choriocapillaris, RPE and photo-
receptor cells (geographic atrophy, GA), while the most common form of wet AMD 
in western countries is the formation of choroidal neovascularisation (CNV) that 
causes oedema and bleeding [75]. In Asia, a subtype termed polypoidal choroidal 
vasculopathy, characterised by haemorrhagic and/or serous detachments of the 
RPE, represents a larger share of wet AMD cases [88, 89]. Even though wet AMD 
accounts for the minority of all AMD cases, this form is devastating since it can 
lead to fast progressing vision loss. Dry AMD advances slower and thus high acuity 
vision can be retained longer. Prevalence for AMD in Germany was estimated as 
11.4 – 11.9% for the early and 0.2% for the late form [90, 91]. Hereafter, the term 
wet AMD will be used to exclusively refer to the CNV-form that is prevalent in Eu-
rope. 
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Figure 6: Schematic depiction of AMD stages (not to scale). In early to intermediate AMD, for-
mation of drusen is characteristic. The stage of disease is only defined by number and size of 
drusen per eye. The overlaying RPE and retina are not injured in this state. In late stage dry AMD, 
drusen become larger or even confluent and RPE and photoreceptor cells are lost (geographic 
atrophy, GA). In late stage wet AMD, neovessels grow from the choriocapillaris through Bruch’s 
membrane (choroidal neovascularisation, CNV) and can either remain below the RPE (occult CNV) 
or break through the RPE into the subretinal space (classic CNV, shown in image). Neovessels are 
malformed and can leak blood and plasma fluid, resulting in oedema (yellow material in subretinal 
space). Own work. 
As aforementioned, AMD is considered to be a multifactorial disease with ad-
vanced age being one of the main risk factors [81]. One of the ultrastructural hall-
marks of the aged retina is the accumulation of the age pigments lipofuscin and 
melanolipofuscin in the RPE (discussed in section 1.2) throughout life. An early 
onset of accumulation of these age pigments can be found in young individuals 
with certain genetic mutations, leading to Stargardt disease.  
1.4.2 Stargardt disease (STGD1) 
One of the most common hereditary diseases that lead to macular degeneration is 
Stargardt disease 1 (STGD1, OMIM #248200), affecting approximately 1 in 10,000 
individuals [92]. The name refers to the German ophthalmologist Karl Bruno Star-
gardt, who described 7 patients from two families affected by the disorder in 1909 
[93]. The autosomal recessive disease is caused by mutations in the ABCA4 gene 
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[94] which encodes a flippase located in the rims of the photoreceptor discs that is 
part of the visual cycle (Fig. 4). A lack of functional ABCA4 protein leads to for-
mation of bisretinoids that are the main constituents of the age pigment lipofuscin 
(section 1.2). It is thought that the early accumulation of extensive lipofuscin and 
the resulting potential cytotoxic burden early in life leads to the retinal degenera-
tion. 
To date, over 1200 disease-causing and disease-associated mutations have been 
identified in the ABCA4 gene [95]. Most of these mutations are related to STGD1, 
but some are also found in cone-rod dystrophy, retinitis pigmentosa and AMD 
[96-100]. A genotype-phenotype model, linking the severity of the mutations in 
ABCA4 to the extent of the retinal damage and thus the resulting disease, has been 
proposed [96, 101, 102]. 
Since there is such a huge genetic variety in STGD1 patients, it is plausible that 
there is also a huge phenotypic variety. Onset varies from early-onset (during 
childhood) to late-onset (later adulthood, historically also referred to as fundus 
flavimaculatus [103]), with a generally better prognosis associated with later on-
set. Typical features include yellow-white flecks in the fundus, atrophic lesions in 
the macula and progressive loss of visual acuity. Drusen, as they are common in 
AMD, are not described in STGD1. Since the clinical presentation of late-onset 
STGD1 and dry AMD can be extremely similar, it is suspected that a considerable 
amount of late-onset STGD1 patients is misdiagnosed with dry AMD [104, 105]. 
Even though this thesis is focused on Stargardt disease 1, two additional sub-
classifications of Stargardt disease, which are much rarer and both inherited in an 
autosomal dominant manner, will be briefly described for the sake of complete-
ness: Stargardt disease 3 (OMIM #600110) is caused by mutations in ELOVL4 
(Elongation of very long chain fatty acids-like 4), a gene important for the for-
mation of very long polyunsaturated fatty acids with 28 and more carbon atoms 
that are incorporated into photoreceptor membranes (reviewed in [106]). Star-
gardt disease 4 (OMIM #603786) is caused by mutations in PROM1 (Prominin-1) 
[107] which encodes a protein crucial in the photoreceptor disc morphogenesis 
[108] and involved in regulating autophagosome maturation and trafficking in the 
RPE [109]. Another classification, Stargardt disease 2, was found to be in error 
and was therefore abolished.  
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Both Stargardt disease 3 and 4 are caused by mutations in genes relevant for the 
photoreceptor outer segment formation; thus, the mutations themselves directly 
induce retinal degeneration since the daily outer segment renewal is hampered in 
their presence. Stargardt disease 1 differs in the sense that the underlying muta-
tions do not affect the upkeep of the retinal structure, but instead provoke in-
creased accumulation of lipofuscin in the RPE, which can be interpreted as accel-
erated aging. This underlines the similarity to particularly the dry form of AMD, 
since both diseases are characterised by formation of geographic atrophy second-
ary to lipofuscin accumulation.  
1.5 AMD and STGD1 intervention 
1.5.1 Current treatment options for AMD and STGD1 
For patients with dry AMD or STGD1, there is currently no treatment available. 
Patients with intermediate AMD can benefit from nutritional supplements con-
taining antioxidants and zinc, which can slow the progression from intermediate 
to advanced AMD [110]. For STGD1 patients, light protection is discussed to be an 
option to reduce disease progression [111]. However, a whole range of different 
approaches, including but not limited to gene therapy, stem-cell transplantation 
and visual cycle inhibitors are under pre-clinical and early clinical investigation for 
both diseases (extensively reviewed in [112]).  
To date, there is no cure for wet AMD, but symptoms may be alleviated. In the 
past, approaches like laser photocoagulation, photodynamic therapy, surgical re-
moval of CNV membranes and others were used, but with limited success since the 
progression of vision loss could at most be reduced but not halted, let alone re-
versed (reviewed in [113] and [114]). Today, to stop the growth and exudation of 
the CNV, current standard treatment is the repeated intravitreal application of 
anti-vascular endothelial growth factor (anti-VEGF) therapeutics (reviewed in 
[115] and [116]). With these drugs, acute deterioration in vision due to oedema can 
be reversed and disease progression can be reduced. However, since this approach 
does not resolve the underlying cause of the disease, treatment has to be continued 
for years with oftentimes monthly or bi-monthly intravitreal injections. This does 
not only result in a high treatment burden for the patient, but some studies sug-
gest that long-term anti-VEGF treatment can lead to the development of yet un-
treatable geographic atrophy [117-119]. 
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The first approved anti-VEGF drug for treatment of wet AMD was pegaptanib 
(Macugen®, OSI Pharmaceutical/Pfizer, FDA approval in 2004, EMA approval in 
2006). Pegaptanib is a PEGylated aptamer that binds specifically to VEGF-A165. 
Since newer drugs are more potent, it is hardly used in wet AMD management an-
ymore.  
Ranibizumab (Lucentis®, Genentech/Novartis) was the next drug approved in 
2006 and 2007 by the FDA and EMA, respectively. Ranibizumab is a 48.3 kDa Fab 
fragment of a humanised monoclonal antibody that binds to all isoforms of VEGF-
A (Fig. 7).  
In 2011/2012, aflibercept (Eylea®, Regeneron/Bayer) was approved by the FDA 
and EMA, respectively. Aflibercept is a recombinant fusion protein consisting of 
the VEGF-binding portions of human VEGF receptor 1 and 2 and a human Immu-
noglobulin G (IgG) backbone with a molecular weight of 115 kDa (Fig. 7). This 
molecule binds to VEGF-A, VEGF-B and placental growth factor with high affinity. 
Due to the higher potency, a better treatment response was expected.  
 
Figure 7: Schematic structures of the most commonly used anti-VEGF drugs ranibizumab (A), 
aflibercept (B) and bevacizumab (C). Domains of heavy chains are depicted in orange, while do-
mains of light chains are painted in yellow. Inter-chain disulphide bridges are shown as black bars. 
Antigen binding domains are shown in dark blue. Aflibercept is a fusion protein that is composed of 
an IgG Fc backbone and domain 3 of VEGF receptor 2 (R2d3) and domain 2 of VEGF receptor 1 
(R1d2). Own work.  
Another frequently used drug, though off-label, is bevacizumab (Avastin®, Roche), 
a 149 kDa recombinant, humanised monoclonal antibody targeted towards all 
isoforms of VEGF-A (Fig. 7). Bevacizumab is only approved for the treatment of 
certain types of metastatic cancer, but since the individual intravitreal dose is very 
cheap (for instance, ranibizumab is 20x to 50x more expensive than bevacizumab, 
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depending on the country [120]), it is frequently used for several ocular diseases 
and was in fact used even before approval of ranibizumab [121].  
An additional drug called conbercept (Lumitin®, Chengdu Kanghong Biotech), a 
143 kDa fusion protein similar to aflibercept, was approved for the treatment of 
wet AMD in China in 2013, but is not used in the rest of the world [122].  
Ranibizumab, aflibercept and bevacizumab show similar clinical outcome and all 
three are routinely used for wet AMD management [123, 124]. In fact, if a patient 
does not respond to a certain anti-VEGF drug, switching to another one is worth 
considering [125-130]. Instead, the question which treatment scheme (for instance 
monthly, as needed (pro re nata), treat-and-extent or observe-and-plan) is the 
most beneficial one has come into focus (reviewed in [131-133]).  
Ophthalmologic use of anti-VEGF compounds is not limited to the treatment of 
wet AMD, but also includes other vascular and oedema-related diseases like dia-
betic macular oedema, retinal vein occlusion, retinopathy of prematurity and oth-
ers [134-140].  
Novel anti-VEGF drugs for wet AMD are currently under clinical investigation. 
The most advanced ones are brolucizumab (Novartis), a 26.3 kDa single-chain var-
iable fragment (scFv) and abicipar pegol (Allergan), a 34 kDa designed ankyrin 
repeat protein (DARPin, both agents reviewed in [141]). The low molecular weight 
of both substances allows higher molar concentrations to be prepared in a single 
intravitreal injection, which may allow elongated intervals between injections and 
thus reduce treatment burden for the patients. Brolucizumab was non-inferior to 
aflibercept in two double-masked randomized phase III trials and over 50% of 
brolucizumab-treated eyes could be maintained on an every-12-weeks dosing in-
terval without reactivation of the disease [142]. The compound is currently under 
FDA review and if approved, market launch is expected by the end of 2019 [143]. 
Abicipar pegol has reached study completion status in two phase III trials (Clini-
calTrials.gov Identifiers: NCT02462486, NCT02462928). 
Since VEGF is not the only growth factor involved in CNV formation, other thera-
peutic routes are also being pursued. One drug under clinical investigation is the 
bispecific antibody faricimab (Roche) that is designed for intraocular use against 
both VEGF and angiopoietin 2 (Ang-2), a growth factor involved in vascular desta-
bilization (reviewed in [144]). The compound consists of two Fab fragments tar-
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geted against VEGF-A and Ang-2, respectively, and an engineered Fc fragment, 
reducing systemic availability and inflammatory potential [145]. Phase II results of 
faricimab for diabetic macular oedema have recently been published [146], phase 
II results for wet AMD are still awaited (ClinicalTrials.gov Identifier: 
NCT03038880). Nevertheless, phase III studies for wet AMD have started in early 
2019 (ClinicalTrials.gov Identifiers: NCT03823287, NCT03823300). 
1.5.2 Adverse events after intravitreal anti-VEGF for wet AMD  
Several types of ocular adverse events have been reported after intravitreal anti-
VEGF application, including transient elevation of the intraocular pressure [124, 
147], subconjunctival haemorrhage [148], rhegmatogenous retinal detachment 
[147] and endophthalmitis [124], but incidence was generally low. It should be 
noted that these types of adverse events are common after intravitreal injections, 
so distinguishing between events due to the procedure and due to the applied 
compound is challenging. However, in animal studies involving Macaca fascicu-
laris (cynomolgus monkey) that were intravitreally injected with bevacizumab, 
ultrastructural analysis revealed that thrombotic microangiopathy, degranulation 
of platelets and neutrophils, blood flow alterations, signs of haemolysis and im-
mune complex formation were present [149-152].  
Systemic adverse events after intravenous application of bevacizumab include hy-
pertension, fatigue, infections, thrombosis, bleeding, gastrointestinal events in-
cluding bowel perforation, proteinuria, delayed wound healing, fistula formation 
and others [153]. To potentially cause systemic adverse events after intravitreal 
injection, anti-VEGF drugs must leave the eye and reach systemic circulation. In 
AMD patients, bevacizumab, aflibercept and ranibizumab can all be found in blood 
plasma and also reduce free VEGF levels after a single intravitreal application 
[154]. The reductive effect was highest for aflibercept and minimal compared to 
baseline for ranibizumab [154]. Furthermore, both bevacizumab and aflibercept 
accumulate in the blood plasma after repeated intravitreal injection and lead to a 
more pronounced reduction of free VEGF levels, while ranibizumab does not have 
this effect [154]. Similar results were found in patients treated for diabetic macular 
oedema [155]. So not only ocular, but potentially also systemic adverse events can 
arise after intravitreal application of anti-VEGF drugs. 
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A 2014 Cochrane review found no differences concerning deaths and serious sys-
temic adverse events within the first two years of intravitreal treatment between 
ranibizumab and bevacizumab, except for gastrointestinal disorders, for which 
there was a higher risk after bevacizumab [156]. Systematic reviews of long-term 
safety data for aflibercept are not yet available, since the drug was only approved 
in 2011/2012. However, recent studies indicate that the intravitreal injection of 
bevacizumab leads to higher mortality of patients with a history of stroke or tran-
sient ischemic attack [157] and is also associated with myocardial infarct within 
2 months after injection, independent of indication for bevacizumab treatment 
[158].  
Adverse events after intravitreal anti-VEGF are rare, but potentially severe since 
they encompass cardiovascular events like thrombotic events, stroke, myocardial 
infarct and others. It is important to note that due to demographic change, the 
prevalence of AMD is expected to rise [159] and that the elderly often show 
comorbidity with diabetes, hypertension and a history of cardiovascular events 
putting them at a higher risk. Since anti-VEGF treatment due to wet AMD has to 
be continued for years, medications with a favourable safety-profile confirmed by 
long-term safety data exceeding 2 years are indispensable. 
An investigation of ultrastructural ocular adverse events after the application of 
aflibercept and ranibizumab in comparison to previous results from bevacizumab 
and an investigation of the role of the Fc fragment in adverse events will be de-
scribed in section 3.3.   
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2 Objectives 
This thesis aims to elucidate the disease progression of the blinding diseases AMD 
and STGD1 (section 3.1), specifying the subcellular origin of NIR-AF that is 
thought to primarily emerge from RPE melanin (section 3.2) and to investigate the 
mechanism behind adverse events of certain frequently used anti-VEGF drugs for 
the management of wet AMD (section 3.3). 
In the first part of this thesis, the disease progressions of AMD and STGD1 are de-
scribed (section 3.1). The natural progression of retinal degeneration was investi-
gated in human donor eye tissue with and without AMD in order to answer the 
long asked question whether RPE or choriocapillaris degeneration is the initial 
step in retinal degeneration due to AMD [1] (section 3.1.1). Since STGD1 is a rare 
disease and thus human donor tissue of affected individuals is scarce, three fre-
quently used STGD1 mouse models and a single human STGD1 eye were employed 
for immunohistochemical and light, fluorescence and electron microscopic inves-
tigation of pathologic processes [5] (section 3.1.2).  
The second part of this thesis deals with a histological approach to identify the 
subcellular origin of NIR-AF seen in fundus autofluorescence [6] (section 3.2). 
While it was already established that the majority of NIR-AF originates from the 
RPE melanin, the extent of contribution of choroidal melanin and potential yet 
unidentified fluorophores was still unclear. Especially the contribution of 
lipofuscin to the NIR-AF was suggested, but not confirmed. Correlation of fluores-
cence and electron microscopy of murine and human tissue, as well as isolated 
porcine ocular melanosomes was therefore used to address this question.  
The third part of this thesis is concerned with adverse events after intravitreal an-
ti-VEGF treatment (section 3.3). To better characterise the adverse event profiles 
of the frequently used anti-VEGF drugs aflibercept and ranibizumab, eyes of in-
travitreally injected monkeys were investigated by immunohistochemistry and 
light and electron microscopy [2, 3]. Pathologic changes in the retina/choroid [2] 
(section 3.3.1) and the iris/ciliary body [3] (section 3.3.2) were investigated. Since 
these two works found that aflibercept induces more ocular adverse events than 
ranibizumab and earlier studies revealed similar adverse events after treatment 
with bevacizumab [150-152], a study to investigate the effect of isolated Fc frag-
ment (that is part of the IgG backbone in aflibercept and bevacizumab, but lacks in 
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ranibizumab) injected intravitreally into the rat eye was conducted [4] (sec-
tion 3.3.3).  
In sum, the present thesis highlights key events in the course of AMD and STGD1 
that might give rise to a better understanding of these diseases and also investi-
gates medical interventions and disease monitoring approaches to advance patient 
diagnostics and treatment.  
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3 Results and discussion 
3.1 Disease progression in AMD and STGD1 
Understanding the cellular and molecular changes in disease is crucial for develop-
ing new therapeutic options. It is well established that photoreceptors, RPE, 
Bruch’s membrane and choriocapillaris form an interdependent complex, which 
means that damage/loss of one tissue results in damage/loss of the other tissues 
(reviewed in [16]).  
Loss of RPE and choriocapillaris has been identified as first step in retinal degen-
eration in AMD in the past, but it has been unclear which of the two tissues is the 
first one to perish [160, 161]. Yet knowing the exact order of tissue degeneration 
would give crucial information about possible underlying mechanistic causes. 
Therefore, a correlated light and electron microscopic study was performed, inves-
tigating tissue of 12 eyes diagnosed with AMD (8 eyes wet AMD, 4 eyes dry AMD; 
ages 71 to 100 years, mean age 82 ± 15 years) and 9 age-matched control eyes 
without known eye disease (ages 57 to 85 years, mean age 75 ± 10 years) [1] (sec-
tion 3.1.1).  
In light microscopic sections, the tissue was graded according to its degradation 
state using a five–stage model, in order to identify transition sites which were lat-
er-on investigated in depth. The focus was put on the transition sites, since there, 
within < 50 µm distance, very abrupt switches between degradation stages oc-
curred. The grading model can be summarised as: healthy (stage I), normal age-
related early changes (stage II), occult CNV, i.e. growth of new vessels beneath the 
RPE but not within the subretinal space (stage III), GA, i.e. loss of outer and inner 
segments of photoreceptors and RPE (stage IV), and classic CNV, i.e. growth of 
new vessels into the neuroretina (stage V). The tissue was investigated for pres-
ence of photoreceptors, RPE cells, deposits between RPE and Bruch’s membrane, 
choriocapillaris vessels, as well as area size of choriocapillaris vessels and chori-
ocapillaris fenestration among others.  
Two approaches were taken: 1) Investigation of whole sections of AMD eyes com-
pared to control eyes, independent of degeneration grading, to obtain overall in-
formation of differences between healthy and diseased tissue. 2) Comparison of 
stages identified at transition sites to gain insight into the disease progress. 
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Analysis of whole sections revealed a loss of photoreceptors, RPE, choriocapillaris 
vessel area and choriocapillaris fenestration, as well as a pronounced formation of 
basal deposits within Bruch’s membrane in AMD tissue compared to control. For 
transition sites, data for each single stage were pooled, independent of the transi-
tion partner stage, giving information about histological changes with AMD pro-
gression. Choriocapillaris was found to be reduced even when RPE was still com-
pletely present, in fact, even control tissue from age-matched donors already 
showed a slight reduction of choriocapillaris. Interestingly, stages I and II of AMD 
donors already had loss of choriocapillaris vessels compared to age-matched 
healthy control tissue that was also graded as stage I and II. When stage II in tran-
sition to stage IV (border zone of GA) was compared to stage II in transition to 
stage V (border zone of CNV), it became evident that stage II in transition to stage 
IV (GA) has a more pronounced loss of RPE and choriocapillaris than stage II in 
transition to stage V (CNV). This suggests that the type of subsequent degenera-
tion is already foreshadowed in stage II areas that by definition only show early 
degenerative changes. However, it is yet unknown whether the border regions re-
ally depict spatiotemporal preliminary stages, but it seems likely. 
This work confirms that the loss of choriocapillaris is the very first step in retinal 
degeneration due to AMD before subsequent loss of RPE and photoreceptors. This 
work also confirms that even healthy aged tissue shows a slight reduction in chori-
ocapillaris, as was also described before [161, 162]. This involvement of chori-
ocapillaris in both the dry and wet form of AMD supports the idea that AMD can 
be considered to be a vascular disease, as has previously been suggested [163-165].  
One interesting finding in two investigated sections was the survival of isolated 
photoreceptor-RPE interfaces in the midst of scar tissue due to CNV formation: in 
these areas, photoreceptors with underlying continuous RPE layer were situated 
above intact CNV vessels (healthy endothelial cells, presence of pericytes), whereas 
in the immediate surroundings, photoreceptors and RPE were absent and CNV 
vessels were damaged (dead endothelial cells, loss of cell contacts between endo-
thelial cells). This observation highlights the natural function of CNV formation as 
a response to hypoxic conditions in AMD [166]. And indeed, subclinical CNV 
without exudation and stable visual acuity has been repeatedly found in patients 
with unilateral wet AMD and has been shown to often remain stable for years [167, 
168]. 
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A difficulty in the investigation of the natural disease process in STGD1 is the scar-
city of donor tissue from affected individuals. Before the start of the present thesis, 
histological characterisations of eyes from only three individual STGD1 donors 
have been published [169-171]. Therefore, a different approach was chosen: three 
STGD1 mouse models frequently used in pre-clinical research, namely pigmented 
Abca4-/-, albino Abca4-/- and pigmented Abca4-/-.Rdh8-/- mice [172-174], were 
longitudinally investigated by light, fluorescence, and electron microscopic meth-
ods up to an age of 25 months [5] (section 3.1.2). In addition, a single human do-
nor STGD1 eye was included, which unfortunately had a very long death-to-
fixation time of 48 hours, so only a limited set of meaningful analysis was possible.  
None of the currently existing STGD1 mouse models fully reflect the situation in 
human STGD1 patients (Table 1). The three different STGD1 mouse models were 
described to vary in their phenotype: although all three strains show the typical 
increased accumulation of lipofuscin compared to their respective wildtype [172, 
175, 176], only the albino Abca4-/- and pigmented Abca4-/-.Rdh8-/- mice were de-
scribed to show overall retinal degeneration with 7 and 3 months, respectively 
[172, 177]. Pigmented Abca4-/- mice lack any signs of retinal degeneration [174, 
175]. 
However, in our hands, the pigmented Abca4-/-.Rdh8-/- mice did not present the 
published retinal rosette formation with 6 weeks and overall retinal degeneration 
with 3 months [174], but instead showed a later onset of degeneration, comparable 
to albino Abca4-/- mice. 
A longitudinal analysis revealed the earliest retinal changes, indicative of retinal 
degeneration, in albino Abca4-/- mice as young as 4 months. These changes in-
cluded ruptured photoreceptor inner segments, disorganised and shortened pho-
toreceptor outer segments, RPE cell-cell contact weakening, and cell detachment. 
Photoreceptor outer segment disorganisation and shortening, as well as RPE de-
tachment first became apparent in 6-month-old pigmented Abca4-/-.Rdh8-/- mice 
and never appeared in pigmented Abca4-/- mice. Ruptured inner segments and 
RPE cell-cell contact did not appear in pigmented mice. Pigmented 
Abca4-/-.Rdh8-/- mice additionally had hypertrophic RPE and the highest levels of 
lipofuscin, quantified as percentage of the RPE cytoplasm occupied by lipofuscin 
and the lipofuscin-moiety of melanolipofuscin. Most of the encountered retinal 
changes in STGD1 mice were previously described in models of oxidative stress of 
RESULTS AND DISCUSSION 
31 
the RPE [178-181] and in fact oxidative stress levels were highest in albino Abca4-/- 
and pigmented Abca4-/-.Rdh8-/- mice.  
Table 1: Overview of characteristics of STGD1 patients and published STGD1 mouse models 
 STGD1 
patient 
pigmented 
Abca4
-/-
 
albino 
Abca4
-/-
 
pigmented 
Abca4
-/-
.Rdh8
-/-
 
pigmented 
Abca4
PV/PV 1
 
Abca4 null mutations 
in both alleles 
no
2 yes yes yes no 
Additional mutated 
genes 
no no no yes3 no 
Accumulation of 
lipofuscin 
yes yes yes yes yes 
Retinal degeneration yes no yes yes no 
Presence of ocular 
melanin  
yes yes no yes yes 
1 The pigmented Abca4PV/PV model [182] has a homozygous knock-in of the L541P;A1038V muta-
tion that leads to early-onset STGD1 in humans [98]. Phenotypically, this model does not differ 
from the pigmented Abca4
-/-
 model, probably due to degradation of the mutated ABCA4 protein 
[182]. To my knowledge, this model has not been used in the literature besides the initial descrip-
tion and was therefore not included in the present work even though it was published prior to the 
start of my study. 
2 Both alleles affected by ABCA4 null mutations were only found in patients diagnosed with auto-
somal recessive retinitis pigmentosa; STGD1 patients have one allele with a null mutation in 
ABCA4 at most [96, 97, 101, 183, 184]. 
3 Mutations in RDH8 are not known to be involved in human diseases (OMIM *608575). 
The fact that signs for retinal degeneration were earliest identifiable in albino 
Abca4-/- mice was somewhat surprising, since pigmented Abca4-/-.Rdh8-/- mice 
were described to have a rather prominent retinal degeneration [174] and their 
genetically induced elevated levels of all-trans-retinal were shown to be highly tox-
ic [185, 186]. Melanin is a known anti-oxidative agent [31, 32] that also fulfils a 
cytoprotective function against oxidative stress in RPE cells [33]. The striking evi-
dence for oxidative stress and early onset of oxidative stress related pathologies in 
albino Abca4-/- mice supports the hypothesis of RPE melanin being a key factor in 
retinal health. However, an important limitation of the study is the differing genet-
ic background of the STGD1 model strains. Since the main goal of this study was 
an ultrastructural comparison of existing and utilised STGD1 mouse models, the 
Abca4 and Rdh8 mutations were not moved onto coisogenic pigmented and albino 
strains. For instance, BALB/c mice (background of albino Abca4-/- mice) were 
shown to have a lower resistance to light-induced retinal damage that is independ-
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ent of pigmentation, compared to 129 mice (background of pigmented Abca4-/- 
mice) [187]. To verify the protective role of RPE melanin against retinal degenera-
tion, further research is therefore needed.  
To conclude, the two publications discussed in this section identify the loss of cho-
riocapillaris as the initial step in retinal degeneration in both wet and dry AMD [1] 
(section 3.1.1) and emphasize on the relevance of melanin for retinal health [5] 
(section 3.1.2). 
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3.1.1 Choriocapillaris breakdown precedes retinal degeneration in age-
related macular degeneration 
 
Authors: Biesemeier A., Taubitz T., Julien S., Yoeruek E., & Schraermeyer U. 
 
Published in Neurobiology of aging in 2014 
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Supplementary Fig. 1. Dry AMD: whole section light microscopical panora-
ma image of a dry AMD donor, female, 93-year-old. The right part of the image 
is exemplarily shown in Fig. 1A. Abbreviation: AMD, age-related macular degen-
eration. 
 
Supplementary Fig. 2. Wet AMD: whole section light microscopical panora-
ma image of a wet AMD donor, male, 76-year-old. The middle part of the image 
is exemplarily shown in Fig. 1B. The box with the numbered CNV vessels refers to 
the vessels investigated for Fig. 6 in the text. CNV 1, 5, 6, 7, and 8 show endothe-
lial lesions when investigated with EM. CNV vessels 2, 3, and 4 are intact. Abbre-
viations: AMD, age-related macular degeneration; CNV, choroidal neovasculariza-
tion; EM, electron microscopy. 
 
Supplementary Fig. 3. Wet AMD: whole section light microscopical panora-
ma image of a wet AMD donor, male, 71-year-old. The left part of the image is 
exemplarily shown in Fig. 2. Abbreviation: AMD, age-related macular degenera-
tion. 
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3.1.2 Ultrastructural alterations in the retinal pigment epithelium and 
photoreceptors of a Stargardt patient and three Stargardt mouse 
models: indication for the central role of RPE melanin in oxidative 
stress 
 
Authors: Taubitz T., Tschulakow A. V., Tikhonovich M., Illing B., Fang Y. 
Biesemeier A., Julien-Schraermeyer S., Schraermeyer U. 
 
Published in PeerJ in 2018 
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Supplemental Figure 1. Retinal pigment epithelium in 12-month-old pig-
mented WT and Stargardt mice. There is no apparent difference in cell size be-
tween pigmented WT and Abca4−∕−, but RPE in Abca4−∕−.Rdh8−∕− mice is hyper-
trophic. DOI: 10.7717/peerj.5215/supp-1 
 
Supplemental Figure 2. Lipid droplets in WT and Abca4−∕−animals. (Top) In 
WT animals, lipid droplets (black arrowheads) often fused with lipofuscin and were 
regularly located in the apical part of the RPE (left: albino WT, 4 months; right: 
pigm. WT, 12 months). (Bottom) Lipid droplets were regularly seen close to the 
basal labyrinth (black arrowheads) in albino Abca4−∕− mice and occasionally in 
pigmented Abca4−∕− mice. Rarely, lipid droplets were also seen apically close to 
the microvilli in albino Abca4−∕− mice (white arrowhead) (left: albino Abca4−∕−, 15 
months; right: pigm. Abca4−∕−, 18 months). DOI: 10.7717/peerj.5215/supp-2  
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Supplemental Figure 3. Immunohistochemical staining of Stargardt mouse 
retinas of 12-month-old animals with anti-HNE, anti-MDA and anti-NITT. Up-
per panels for each primary antibody show negative controls (primary antibody 
was omitted); bottom panels for each primary antibody show the respective anti-
body stain (red). 
DOI: 10.7717/peerj.5215/supp-3  
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3.2 Identifying the source of fundus near-infrared autofluorescence 
A major non-invasive examination technique used for disease diagnostics and 
monitoring in ophthalmology is fundus autofluorescence that is based on the visu-
alisation of autofluorophores in the back of the eye. Conventional fundus autofluo-
rescence uses SW-AF (excitation 488 nm), which is an established marker for 
lipofuscin in the RPE [62]. Therefore, SW-AF can be used to either monitor the 
accumulation and distribution of lipofuscin or instead as a substitute marker for 
the whole RPE. SW-AF is applicable in a wide range of retinal disorders, including 
but not limited to drug toxicity, tissue defects (such as macular hole and RPE 
tears) as well as inherited and acquired retinal dystrophies such as STGD1 and 
AMD (reviewed in [65]). NIR-AF (excitation 787 nm) on the other hand is a more 
recent development and of high interest as an early disease marker and as poten-
tial endpoint in patient studies, since NIR-AF changes occur in many retinal dis-
eases and oftentimes precede changes in SW-AF patterns [67-72]. However, the 
origin of NIR-AF is still being discussed: melanin in both the RPE and choroid has 
been identified as the main source [63, 64, 66], while involvement of lipofuscin is 
disputed [66, 69].  
Since the spatial resolution of fundus autofluorescence is limited, a histological 
approach combining light, fluorescence and electron microscopy was chosen to 
identify the subcellular origin of NIR-AF [6] (section 3.2.1).  
Melanosome-derived NIR-AF intensity in the RPE and the choroid increased with 
age in both WT and Abca4-/- mice. But NIR-AF intensity varied between melano-
somes: In the choroid, some melanosomes appeared indistinguishable in bright 
field, but differed vastly in their NIR-AF intensity. In RPE cells of young mice, the 
spindle-shaped melanosomes had very weak NIR-AF that did not span the whole 
granule profile, while spherical melanosomes showed a high variety in NIR-AF 
intensity. In RPE cells of aged mice, almost all melanosomes showed high NIR-AF 
intensity over the whole profile.  
In aged WT (18 months) and young Abca4-/- mice (7 months) that have compara-
ble levels of lipofuscin, some areas exhibiting SW-AF also showed NIR-AF. Since 
these areas with superimposed SW- and NIR-AF were in close proximity to bright 
field-confirmed melanosomes, it is plausible to assume that these areas are the 
lipofuscin moiety of melanolipofuscin. In aged Abca4-/- mice (13 months) however, 
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also SW-AF positive areas that were spatially separated from bright field-
confirmed melanosomes showed NIR-AF, suggesting that in these animals also 
true lipofuscin granules emit NIR-AF.  
In albino Abca4-/- mice however, no specific NIR-AF signals co-localizing with 
SW-AF signals were found; only very weak NIR-AF signals, comparable to back-
ground intensity, were detectable when using prolonged acquisition times. It is 
plausible that these weak NIR-AF signals in albino Abca4-/- mice have a differing 
molecular origin. Most likely the signal is fluorescence spillover due to the broad 
range of emitted wavelengths of the variety of fluorophores in lipofuscin.  
To corroborate the findings from mice, eye tissue of two human donors (68 and 
80 years) without known ophthalmic diseases was investigated. Correlative fluo-
rescence and electron microscopy on single tissue sections was used to clearly at-
tribute the two types of autofluorescences to the different RPE pigment types: vir-
tually all lipofuscin granules identified by EM showed strong signals in SW-AF and 
additional signals in NIR-AF. Melanolipofuscin granules showed a NIR-AF-
positive but SW-AF-negative melanin core and a NIR- and SW-AF-positive shell of 
lipofuscin. Melanosomes showed only NIR-AF, but never SW-AF. This confirmed 
that also in aged human donor eyes without ocular disease, NIR-AF is not only 
emitted from melanin, but also from lipofuscin and the lipofuscin moiety of 
melanolipofuscin.  
AF of melanin was previously described after photic and oxidative stress [188-
192], so it was investigated whether NIR-AF can also be induced by these noxious 
factors. Porcine melanosomes isolated from choroid and RPE were exposed to ei-
ther white light or hydrogen peroxide, respectively. RPE melanosomes showed an 
increase of NIR-AF after both treatments, while choroidal melanosomes only 
showed a significant increase after 6 hours of hydrogen peroxide treatment. This 
verifies that melanin NIR-AF increases with both photic and oxidative stress, alt-
hough the two granule types react to a different extent. Nevertheless, this can 
serve as an explanation of the observed age-dependent increase of melanosome-
derived NIR-AF in WT and pigmented Abca4-/- mice. Furthermore, an in vivo 
phototoxicity model of advanced STGD1 was used, in which pigmented Abca4-/- 
mice are illuminated with blue light to induce a light-depended RPE and retinal 
changes similar to the situation in patients with advanced STGD1 [193]. In this in 
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vivo model, melanosomes and lipofuscin granules in the RPE showed higher NIR-
AF in illuminated eyes than in unilluminated ones, confirming the in vitro results.  
But how can melanosome-based NIR-AF that can be induced by photic or oxida-
tive stress be reconciled with lipofuscin-based NIR-AF? It was shown that oxida-
tion of eumelanin (which is the main type of melanin in both the RPE and choroid) 
results in the formation of degradation products that are highly autofluorescent 
[191]. The biological fate of these degradation products is not known to date. How-
ever, elemental analysis of human RPE pigments found that the lipofuscin moiety 
of melanolipofuscin has significantly elevated nitrogen levels compared to 
lipofuscin granules [46, 47]. Generally, nitrogen is considered to be a marker for 
protein, but also melanin and the aforementioned autofluorescent melanin degra-
dation products contain nitrogen [191]. It is conceivable that autofluorescent mel-
anin degradation products accumulate in the lipofuscin moiety of melano-
lipofuscin granules, which could explain the finding of co-localized SW- and NIR-
AF in close association to bright field-confirmed melanosomes in mice. Melano-
somes and lipofuscin granules, and therefore also melanolipofuscin granules, be-
long to the lysosomal compartment [19, 41]. Melanosomes were shown to be able 
to fuse with phagosomes [194] and dynamic processes involving lipofuscin gran-
ules, such as fusion of lipofuscin with primary and secondary lysosomes, have 
been suggested before [195]. By such dynamic and exchange processes, NIR-AF 
positive melanin degradation products might amass in lipofuscin granules. 
Lipofuscin-derived NIR-AF being caused by melanin degradation products would 
also explain why individual lipofuscin granules in albino Abca4-/- mice show no 
NIR-AF exceeding background NIR-AF. 
However, trafficking between melanosomes and lipofuscin granules has not been 
described to date. Also, molecular confirmation of presence of melanin degrada-
tion products in lipofuscin is yet lacking. This is in part due to most chemical anal-
ysis of lipofuscin composition being based on Folch extraction which only allows 
the analysis of chloroform soluble lipids. 
Nevertheless, this study shows that NIR-AF is not an intrinsic property of melano-
somes and can under certain conditions also arise from lipofuscin granules. This is 
not only relevant for refined diagnostics of patient NIR-AF data, but also opens the 
possibility to gain deeper insights into pathomechanisms in melanin and 
lipofuscin-derived diseases.   
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3.2.1 Age, lipofuscin and melanin oxidation affect fundus near-infrared 
autofluorescence  
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Supplementary Information  
 
 
Figure S1. Semi-quantitative analysis of total NIR-AF (left) and BF (right) intensities 
derived from RPE and choroid of WT mice (N = 7-11 pictures per group, # p < 0·01, 
* p < 0·0001, Dunnett’s test). AF: autofluorescence; BF: bright field; IOD: integrated opti-
cal density; NIR: near-infrared. 
 
 
Figure S2. Choroidal melanosomes differ in their NIR-AF properties. Bright field and 
post-processed NIR-AF micrographs of an 18-month-old WT mouse. Boxed areas in a) 
are shown magnified in b). Even though melanosomes have similar size and density in 
bright field, they can show either very intense (black arrows) or very weak (white arrows) 
NIR-AF. Also note the large, roundish cells with high levels of NIR-AF in the choroid that 
are macrophage-like cells (compare with Fig. 2). BF: bright field; NIR: near-infrared. 
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Figure S3. Comparison of 7- and 13-month-old pigmented Abca4-/- mice. a) Overview 
of RPE and choroidal NIR-AF (red) taken under identical conditions. Note the large, roun-
dish cells with high levels of NIR-AF in the choroid of the 13-month-old animal that are 
macrophage-like cells (compare with Fig. 2). b) Magnified BF and NIR-AF (red) and SW-
AF (green) images of the RPE areas shown in (a). AF images were post-processed to 
allow the localization of weak signals. White arrows point to lipofuscin with prominent NIR-
AF signal, resulting in yellow colour in overlay images, while black arrows point to 
lipofuscin with no or limited NIR-AF signal, resulting in green colour in overlay images. 
Boxed areas are magnified in (c). c) Magnified images of the boxed areas in (b). Top row 
shows black arrow areas, bottom row shows white arrow areas. BF: bright field; 
NIR: near-infrared; SW: short wavelength.  
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Figure S4. Autofluorescence in the RPE of a 12-month-old albino Abca4-/- mouse. 
The bright field image shows no tissue structures due to lack of melanin in albino animals 
and no additional staining. AF images were post-processed to allow the localization of 
weak signals. Areas exhibiting both AF modalities are yellow in the superimposed image. 
Few lipofuscin granules show NIR-AF signals (white arrowheads) that are not stronger 
than background signals derived from RPE and choroidal nuclei (black arrowheads). 
BF: bright field; NIR: near-infrared; SW: short wavelength. 
 
 
Figure S5. Autofluorescence and electron microscopy of the RPE of a 80-year-old 
human donor. a) NIR-AF (red) and SW-AF (green) images were post-processed to allow 
the localization of weak signals. Yellow colour shows areas where NIR-AF and SW-AF 
superimpose. In aged human RPE, melanosomes (white arrows) are reduced and mostly 
found apically. Many BF-identified melanosomes are surrounded by SW-AF identified 
lipofuscin, indicative of melanolipofuscin (grey arrows). Lipofuscin granules are marked 
with black arrows and predominantly show both NIR- and SW-AF. b) Routine ultrastruc-
tural image (post-fixed with osmium tetroxide, stained with uranyl acetate and lead citrate) 
from the same eye, pigment granules are labelled identical as in a). BF: bright field; 
NIR: near-infrared; SW: short wavelength.  
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Figure S6. NIR-AF and SW-AF of isolated human RPE granules (46 – 91 years old, 
mean age 70·2 ± 14·7 years). a) RPE granules were separated by density gradient cen-
trifugation into three fractions containing lipofuscin (L), melanolipofuscin (ML) and melanin 
(M), respectively. b) NIR-AF (red) and SW-AF (green) images of isolated granules were 
post-processed to allow the localization of weak signals. Yellow colour in NIR-/SW-AF 
overlay images shows areas where NIR-AF and SW-AF superimpose. Insets show mag-
nifications of the boxed areas. c) Electron micrographs of granules from the three isolated 
fractions. Note that granules are surrounded by extragranular debris (asterisks), as has 
been described before1. BF: bright field; NIR: near-infrared; SW: short wavelength.  
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Figure S7. Porcine RPE and choroidal melanosomes after photic and oxidative 
stress. Isolated melanosomes were either kept in the dark (control) or treated with white 
light (45,000 lux) or with 0·3% hydrogen peroxide at pH 7·4 for 3 to 6 hours, respectively. 
a) Representative NIR-AF and BF images of the different groups. b) Semi-quantitative 
analysis of melanosome darkness in bright field images. Choroidal melanosomes react 
more readily with granule brightening than RPE melanosomes, while RPE melanosomes 
predominately react to photic and oxidative stress with presence of NIR-AF (see Fig. 7 in 
main text). (N = 4-6 images per group, ‡ p < 0·05, # p < 0·01, * p < 0·0001, Dunnett’s 
test). BF: bright field; IOD: integrated optical density; NIR: near-infrared. 
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Figure S8. Ultrastructural changes of porcine RPE and choroidal melanosomes af-
ter photic and oxidative stress. Control RPE melanosomes have a relatively homoge-
nous electron dense presence and occasionally show small holes close to the granule 
edge (arrowheads). After treatment with white light, these holes appear more often in 
RPE melanosomes and seem to increase in size. Individual melanosomes present with 
numerous big holes throughout the granule profile (arrow). In hydrogen peroxide treated 
RPE melanosomes, the holes are less prominent, but the formerly relative homogenous 
electron density appears striated. In choroidal melanosomes, ultrastructural changes are 
much less prominent. Note that granules are surrounded by extragranular debris (aster-
isks), as has been described before1. 
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3.3 Treatment of wet AMD: the influence of the Fc fragment in anti-
VEGF adverse events 
In the past, the group of Prof. Dr. Schraermeyer extensively investigated the ef-
fects of intravitreal injection of bevacizumab in monkey eyes [149-152, 196-199]. 
Key findings were thrombotic microangiopathy, signs of haemolysis, formation of 
immune complexes, and blood flow alterations within one to 14 days after a single 
intravitreal injection of bevacizumab [149-152]. The formation of immune com-
plexes by bevacizumab was first described to be a reaction between bevacizumab, 
VEGF-A165 and heparin involving the FcγRIIa receptor on thrombocytes [200] and 
was supposed to be the reason for the elevated risk of arterial thromboembolic 
events in patients with metastatic tumours treated with a combination of bevaci-
zumab and chemotherapy [201]. However, bevacizumab, VEGF-A165 and heparin 
can also form immune complexes in vitro on endothelial cells, while ranibizumab, 
lacking an Fc fragment, does not [149].  
The effects of a single intravitreal injection of ranibizumab and aflibercept into the 
monkey eye [2, 3] (sections 3.3.1 and 3.3.2) were investigated in a similar manner 
to bevacizumab [150-152, 196, 199, 202].  
One day after a single injection, both ranibizumab and aflibercept were located in 
retinal and choroidal vessels. Ranibizumab permeated the neuroretina via inter-
cellular clefts, while aflibercept was incorporated into ganglion cells. Ranibizumab 
and aflibercept were found to both reduce the lumen of the choriocapillaris one 
and seven days after a single intravitreal injection, as was previously found for 
bevacizumab [150]. This is in accordance with studies showing that free VEGF is 
essential for the upkeep of the choriocapillaris [203]. Choriocapillaris fenestration 
loss, microangiopathy and haemolysis were more pronounced after aflibercept 
than after ranibizumab. These findings were also previously observed after bevaci-
zumab [150-152]. Hypertrophy and death of RPE, as well as the formation of pro-
tein complexes, representing as abundant fibrous material seemingly attaching 
erythrocytes to each other or to endothelial cells and thus reducing blood flow, 
were only evident after treatment with aflibercept and not after ranibizumab. The 
lack of abundant protein complexes after in vivo application of ranibizumab is 
consistent with the lack of immune complex formation in vitro [149]. 
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One day after intravitreal injection, both ranibizumab and aflibercept were located 
in the walls of ciliary blood vessels, on the surface layer of the ciliary epithelium 
and in the connective tissue surrounding the vascular plexus, similar to the distri-
bution pattern of bevacizumab in the ciliary body [199]. Both drugs induced a 
comparable reduction of free VEGF in the non-pigmented epithelium of the ciliary 
body and lead to a reduction of ciliary blood vessel fenestration. The reduction of 
free VEGF in the ciliary body epithelium by both drugs verifies the usefulness of 
anti-VEGF drugs in anterior segment pathologies, such as rubeosis iridis [140, 
204]. However, exclusively in aflibercept-treated irides, vacuolisation of the inte-
rior iris pigment epithelium was evident after one and seven days after injection. 
The nature and relevance of these vacuoles remain to be elucidated.  
In summary, studies involving monkeys showed that the most numerous and se-
vere pathologies after intravitreal application of anti-VEGF compounds were en-
countered after bevacizumab and aflibercept. Notably microangiopathy, haemoly-
sis and protein complex formation, which were exclusively found after bevaci-
zumab [150-152] and aflibercept, are alarming outcomes, especially when one 
takes the systemic accumulation of these drugs after repeated intravitreal applica-
tion into account [154].  
It is unclear, whether aflibercept is actually able to induce immune complex for-
mation by the mechanism described for bevacizumab [200], since it is not known 
how VEGF is bound by the fusion protein aflibercept and whether the heparin-
binding site of VEGF needed for complex formation is still accessible. However, 
since treatment with ranibizumab resulted in fewer and less severe pathologies 
than treatment with aflibercept and bevacizumab, it suggested itself that the mo-
lecular structure of the drugs, i.e. the presence or lack of an Fc domain, might have 
an impact on the observed pathologies. 
To investigate the effects of isolated Fc domains, rats were intravitreally injected 
with isolated rat Fc at a dose corresponding to the Fc fragment dose in anti-VEGF 
treatment in patients [4] (section 3.3.3). Thrombotic events, such as fibrin for-
mation, as well as activation and loose aggregation of thrombocytes, were fre-
quently observed at all time points after Fc fragment injection, but only infre-
quently in controls. These findings are in accordance with the aforementioned 
studies in monkeys, where treatment with both bevacizumab and aflibercept (both 
containing an Fc domain) resulted in a pronounced occurrence of thrombotic 
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events and stasis [2, 150, 151]. However, the most prominent finding after applica-
tion of Fc fragments was the infiltration of immune cells in the vitreous-retina in-
terface as early as one day after injection. The majority of cells in the vitreous were 
identified as macrophages by immunohistochemical analysis, but ultrastructurally, 
also granulocytes were identified. The observation of infiltrating cells was unex-
pected, since this was not seen in the earlier studies involving monkeys. However, 
a meta-study reported a significantly increased risk to develop a sterile endoph-
thalmitis after intravitreal injection of bevacizumab compared to ranibizumab 
[205] which might be connected to these findings.  
Fc cannot only directly be related to drug-induced pathologies, but also indirectly: 
IgG is known to be “recycled” and protected from catabolism by binding to the ne-
onatal Fc receptor [206], elongating the serum half-live of the IgG. This process is 
utilised for therapeutic Fc-fusion proteins [207] and might also be the reason for 
the accumulation of bevacizumab and aflibercept in contrast to ranibizumab in 
patient serum [154]. However, since the vast majority of pathologies in the mon-
key studies were already present one day after injection, this process probably only 
plays a minor role in this context.  
The present works [2, 3] (sections 3.3.1 and 3.3.2) show that after application of 
Fc-containing anti-VEGF drugs, more numerous and severe pathologies, such as 
microangiopathy, haemolysis and blood flow alterations, were present in monkey 
eyes, which was not the case after applying the Fc-less ranibizumab. Furthermore, 
even individual Fc fragments without any therapeutic effect induced thrombotic 
events and infiltration of immune cells into the vitreous-retina interface after a 
single intravitreal injection in a rat model [4] (section 3.3.3).  
These data point to Fc-containing anti-VEGF drugs having an unfavourable safety 
profile, especially considering that AMD patients treated with anti-VEGF are el-
derly and often suffer from systemic diseases affecting cardiovascular health. Fur-
thermore, since anti-VEGF intervention treats the symptoms, but not the underly-
ing cause of wet AMD, treatment has to be continued for potentially years, which 
gives rise to possible long-term effects, particularly since Fc-containing anti-VEGF 
drugs were shown to accumulate after repeated intravitreal injection [154]. How-
ever, there is currently no consensus whether the established anti-VEGF drugs 
have different safety profiles [124, 147, 156, 208-210] and more research is needed.   
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3.3.1 Different effects of intravitreally injected ranibizumab and afliber-
cept on retinal and choroidal tissues of monkey eyes. 
 
Authors: Julien S., Biesemeier A., Taubitz T., Schraermeyer U. 
 
Published in The British Journal of Ophthalmology in 2014 
DOI: 10.1136/bjophthalmol-2013-304019 
 
This work was conducted as a student research assistant and is included since it 
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3.3.2 The effects of VEGF-A-inhibitors aflibercept and ranibizumab on 
the ciliary body and iris of monkeys. 
 
Authors: Ludinsky M.*, Christner S.*, Su N., Taubitz T., Tschulakow A., Biesemei-
er A., Julien-Schraermeyer S., Schraermeyer U. 
 
*Maximilian Ludinsky and Sarah Christner are both first authors.  
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2016 
DOI: 10.1007/s00417-016-3344-8 
 
Declaration of own contributions: 
The manuscript was planned by Prof. Dr. Ulrich Schraermeyer and PD Dr. Sylvie 
Julien-Schraermeyer. Experimental procedures and data acquisition were per-
formed by Maximilian Ludinsky, Nan Su and me, I performed the sample prepara-
tion (tissue preparation, embedding and sectioning). Data was analysed by Maxi-
milian Ludinsky, Dr. Sarah Christner, Nan Su, Dr. Alexander Tschulakow and 
Prof. Dr. Schraermeyer. The manuscript was written by Maximilian Ludinsky, Dr. 
Sarah Christner and Nan Su. I proof-read the manuscript with the other authors 
and performed the revision in collaboration with Maximilian Ludinsky, Dr. Sarah 
Christner, PD Dr. Antje Biesemeier and PD Dr. Sylvie Julien-Schraermeyer. 
 
  
RESULTS AND DISCUSSION 
124 
 
 
Reprinted by permission from Springer Nature Customer Service Centre GmbH: Springer, Graef Arch Clin Exp, The effects 
of VEGF-A-inhibitors aflibercept and ranibizumab on the ciliary body and iris of monkeys, Ludinsky et al., 2016
RESULTS AND DISCUSSION 
125 
 
 
Reprinted by permission from Springer Nature Customer Service Centre GmbH: Springer, Graef Arch Clin Exp, The effects 
of VEGF-A-inhibitors aflibercept and ranibizumab on the ciliary body and iris of monkeys, Ludinsky et al., 2016  
RESULTS AND DISCUSSION 
126 
 
 
Reprinted by permission from Springer Nature Customer Service Centre GmbH: Springer, Graef Arch Clin Exp, The effects 
of VEGF-A-inhibitors aflibercept and ranibizumab on the ciliary body and iris of monkeys, Ludinsky et al., 2016  
RESULTS AND DISCUSSION 
127 
 
 
Reprinted by permission from Springer Nature Customer Service Centre GmbH: Springer, Graef Arch Clin Exp, The effects 
of VEGF-A-inhibitors aflibercept and ranibizumab on the ciliary body and iris of monkeys, Ludinsky et al., 2016
RESULTS AND DISCUSSION 
128 
 
 
Reprinted by permission from Springer Nature Customer Service Centre GmbH: Springer, Graef Arch Clin Exp, The effects 
of VEGF-A-inhibitors aflibercept and ranibizumab on the ciliary body and iris of monkeys, Ludinsky et al., 2016  
RESULTS AND DISCUSSION 
129 
 
 
Reprinted by permission from Springer Nature Customer Service Centre GmbH: Springer, Graef Arch Clin Exp, The effects 
of VEGF-A-inhibitors aflibercept and ranibizumab on the ciliary body and iris of monkeys, Ludinsky et al., 2016  
RESULTS AND DISCUSSION 
130 
 
 
Reprinted by permission from Springer Nature Customer Service Centre GmbH: Springer, Graef Arch Clin Exp, The effects 
of VEGF-A-inhibitors aflibercept and ranibizumab on the ciliary body and iris of monkeys, Ludinsky et al., 2016  
RESULTS AND DISCUSSION 
131 
 
 
Reprinted by permission from Springer Nature Customer Service Centre GmbH: Springer, Graef Arch Clin Exp, The effects 
of VEGF-A-inhibitors aflibercept and ranibizumab on the ciliary body and iris of monkeys, Ludinsky et al., 2016  
RESULTS AND DISCUSSION 
132 
 
 
Reprinted by permission from Springer Nature Customer Service Centre GmbH: Springer, Graef Arch Clin Exp, The effects 
of VEGF-A-inhibitors aflibercept and ranibizumab on the ciliary body and iris of monkeys, Ludinsky et al., 2016  
RESULTS AND DISCUSSION 
133 
3.3.3 Effects of intravitreally injected Fc fragment on rat eyes. 
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3.4 Conclusion and future perspectives 
Unravelling the pathogenesis of multifactorial diseases, such as AMD, is a complex 
and challenging task. In addition to several genes involved in the complement sys-
tem, lipid metabolism, extracellular matrix formation and others [84-87], envi-
ronmental factors, such as nutrition (e.g. uptake of antioxidants) [110] and habits 
(e.g. smoking) [211, 212], play an essential role in AMD genesis and progression. 
All these factors may have an immediate impact on the disease course and maybe 
even on the route AMD takes – development of the dry or wet form in the final 
disease stage.  
In the present work, a loss of choriocapillaris was identified as the initial step in 
early stages of AMD [1] (section 3.1.1). In fact, even in healthy aged donor eyes a 
slight reduction was present [1], as was also described before [161, 162].  
For diagnosis and monitoring of retinal alterations in AMD and other retinal dis-
eases, optical coherence tomography (OCT) is routinely employed. In this tech-
nique, coherent light is used to generate micrometre-resolution images of optically 
scattering materials, such as biological tissue. In 2012, an advanced technique, 
called OCT angiography, was introduced that allows the visualisation of retinal 
and choroidal blood flow without additional dye injection [213]. Reduction of cho-
riocapillaris density outside of GA has recently been confirmed by OCT angi-
ography and is discussed as potential endpoint for clinical interventional GA trials 
[214, 215]. Whether choriocapillaris density is also affected in inherited retinal 
dystrophies is currently unknown, but choroidal vascularity was shown to be re-
duced in retinitis pigmentosa, cone-rod dystrophy and STGD1 [216]. 
On a molecular level, reduced blood flow due to a loss of choriocapillaris results in 
hypoxia, an inadequate supply of oxygen. Furthermore, AMD is characterised by a 
low chronic inflammation [217]. Elevated cellular metabolism due to inflammation 
might even increase oxygen consumption, further deteriorating the situation. The 
group of Prof. Dr. Schraermeyer showed in an ex vivo model that under hypoxic 
conditions, the endothelial cells of the choriocapillaris express Hif-1α and VEGF, 
lose contact to each other and develop fenestrated microvillar projections into the 
vessel lumen that can form a labyrinth (Tikhonovich MV, et al. Invest Ophthalmol 
Vis Sci. 2017;58:ARVO E-Abstract 4078). Capillaries with impaired endothelial 
cell connections and microvillar projections were previously found in CNV mem-
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branes and termed “labyrinth-like capillaries” [218]. Since the labyrinth-like pro-
jections prevent cellular blood components, but not plasma, from passing through 
the vessel, leakages due to insufficient endothelial connections cannot be halted by 
thrombocytes [218]. 
In AMD, inflammation is not only limited to the retina and the choroid, but can 
also be found systemically [219]. Moreover, gout, a systemic inflammatory disease 
that also promotes oxidative stress, was found to be associated with an elevated 
risk to develop AMD [220]. Oxidative stress and retinal inflammation were also 
found in mouse models of STGD1 previously [177, 221] and in the present work [5] 
(section 3.1.2) .  
As aforementioned, melanin is a potent antioxidant that exists in high levels in 
both the RPE and the melanocytes of the choroid. RPE melanin was shown to be 
an immune response modulator [222]. Tyrosinase, the key enzyme in melanin bio-
synthesis, was found to be a potential factor in AMD genetics [86] and prevalence 
of AMD is lower in individuals of African descent [80, 223, 224]. This highlights 
the relevance of ocular melanin in health and disease and warrants further investi-
gation. An important limitation of the study presented in section 3.1.2 [5] is that it 
was not designed to test for melanin effects. In fact, the major goal of this study 
was an ultrastructural comparison of the STGD1 mouse models to gain more in-
sight into their pathology and to evaluate their strengths and weaknesses as dis-
ease models. As previously described in the literature, there were no signs of reti-
nal degeneration in pigmented Abca4-/- mice. Albino Abca4-/- mice however 
showed an unexpected earlier onset of retinal degeneration compared to 
Abca4-/-.Rdh8-/- mice, although Abca4-/-.Rdh8-/- mice have a higher genetic bur-
den that results in high levels of cytotoxic free all-trans-retinal [172]. However, 
earlier onset of retinal degeneration in albino Abca4-/- mice is in accordance with 
the hypothesis that melanin might be a key factor in retinal health. This is sup-
ported by the vast literature highlighting the relevance of melanin in the RPE, but 
nevertheless, future studies are inevitable to elucidate the specific effects of RPE 
melanin. A main issue in this endeavour is the abundance of melanin in the 
eye: melanin is not only present in the RPE, but also in the choroid and the iris. 
Especially the iris melanin may not be overlooked, since more light can travel 
through albinistic irides, resulting in a higher illumination of the fundus of the eye. 
This in itself might result in damages that might be falsely attributed to the lack of 
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RPE melanin. The use of conditional knock-out and knock-in models (for instance, 
pigmented animals with a conditional knock-out of tyrosinase in the RPE, result-
ing in albinistic RPE in an otherwise pigmented eye) would be an invaluable asset.  
In recent times, the investigation of fundus NIR-AF has attracted attention, since 
in many retinal diseases, characteristic changes in NIR-AF occur and sometimes 
even precede changes in SW-AF patterns [67-72]. The work presented in section 
3.2.1 [6] shows that not only RPE and choroidal melanin, but also the lipofuscin 
moiety of melanolipofuscin and lipofuscin granules can emit relevant levels of 
NIR-AF. The work also demonstrates that both oxidative and photic stress in-
creases melanosome-derived NIR-AF. This suggests that NIR-AF is not an intrin-
sic property of melanin but should rather be considered to be a marker for aged 
and/or damaged melanin. The fact that pigmented Abca4-/- mice showed higher 
intensity of NIR-AF than pigmented WT mice, is in accordance with the higher 
levels of oxidative stress due to accumulation of lipofuscin in these mice. This also 
supports the notion that ocular melanin can act as a “wear and tear” material that 
is meant to quench oxidative stress at its own expense and thereby reduce the oxi-
dative burden of the surrounding tissue, as suggested in the study presented in 
section 3.1.2 [5]. However, future research is needed to investigate whether the 
NIR-AF signal derived from lipofuscin is in fact due to accumulation of melanin 
degradation products. Nevertheless, these findings urge to rethink the interpreta-
tion of NIR-AF patterns in retinal diseases. Currently, new non-invasive imaging 
techniques are being developed that for instance are potentially able to distinguish 
between lipofuscin and melanolipofuscin granules [225, 226]. Such techniques in 
combination with a refined interpretation of already established techniques, such 
as NIR-AF, have the potential to advance the understanding of both the biogenesis 
and the diagnostics of retinal diseases.  
However, the influence of melanin is by far not the only open question left in un-
derstanding macular degenerative diseases. For instance, a very compelling issue 
is the question which mechanism triggers the development of either the wet or the 
dry form of AMD. Furthermore, both AMD and STGD1 patients have high levels of 
RPE lipofuscin, and even though the lipofuscin component A2E was shown to be 
pro-angiogenic [54, 55], only patients with wet AMD develop CNV, while CNV was 
never described in STGD1 and was also not seen in the three STGD1 mouse strains 
investigated in section 3.1.2 [5]. Even though a plethora of associated genes and an 
RESULTS AND DISCUSSION 
147 
extensive list of molecular and cellular changes have been identified in AMD, link-
ing the disease to oxidative stress, lipid metabolism and mitochondrial malfunc-
tion among others, there is still a lack in understanding how these factors deter-
mine the disease progression. Deciphering these interconnections and finding bet-
ter treatment options will undoubtedly be challenging, but will be invaluable due 
to the expected rise in AMD patients in future years. But also the pathology of 
STGD1 leaves a series of open questions that warrant further investigation. The 
probably most intriguing one is the variety in ABCA4-related disease: As men-
tioned briefly in section 1.4.2, mutations in ABCA4 are not only found in STGD1, 
but also in other retinal degenerative diseases, such as cone-rod dystrophy, retini-
tis pigmentosa and AMD. Therefore, a genotype-phenotype model was suggested 
[96-100]. In this model, STGD1 is caused by rather mild mutations (e.g. mutations 
leading to reduced protein functionality) in both alleles or a mild and a severe mu-
tation (e.g. mutations leading to complete loss of function) in one allele of ABCA4, 
respectively. On the other hand, two severe mutations in both alleles of ABCA4 
always lead to autosomal recessive retinitis pigmentosa [97, 101, 183, 184], a dis-
ease that has a very different phenotype compared to STGD1: the first clinical 
symptom is night blindness, followed by progressive loss in peripheral vision and 
subsequent loss in central vision [227]. How different defects in a single gene can 
lead to so vastly different diseases is astonishing and not yet understood. A recent 
study indicates that Abca4 is not only expressed in photoreceptors, but also in the 
RPE, and suggests that RPE-ABCA4 is also involved in lipofuscin accumulation 
[43]. Furthermore, the macula is predominated by cones, while in the periphery 
only rods exist. Differences in the metabolism of these different photoreceptor 
species are not yet fully understood but might play a role in the photoreceptor’s 
reaction to various ABCA4 defects and impaired RPE due to lipofuscin accumula-
tion, and the resulting implications.  
Even though the molecular mechanisms in macular degeneration are not yet com-
pletely understood, at least for wet AMD the treatment with anti-VEGF com-
pounds turned out to be successful in reversing acute visual distortion due to oe-
dema and reducing disease progression. However, as outlined in the studies pre-
sented in section 3.3, anti-VEGF compounds show certain adverse effects that 
might be mediated by their Fc moiety. There are new anti-VEGF compounds cur-
rently under FDA review or in phase III for treatment of wet AMD, namely brolu-
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cizumab and abicipar pegol, respectively, both lacking Fc fragments and both with 
a molecular weight lower than that of ranibizumab. This potentially reduces not 
only the likeliness of systemic adverse events due to reduced systemic accumula-
tion, but the low molecular weight also gives the possibility of applying high dos-
ages with a single intravitreal injection. This might act as a depot, reducing the re-
injection frequency and thus leading to a higher patient compliance, since high-
frequent re-injections, as often as monthly, are often perceived as a burden by pa-
tients. And in fact, phase III trials of brolucizumab showed that 50% of treated 
eyes could be maintained on an every-12-weeks dosing scheme [142]. But the rele-
vance of the Fc fragment is also considered in other therapeutic approaches: For 
instance, in the bispecific antibody faricimab that is targeted against both VEGF 
and Ang-2, the Fc fragment is engineered to prohibit binding to all Fcγ receptors 
and the neonatal Fc receptor, reducing systemic availability and inflammatory po-
tential [145].  
However, some studies suggest that prolonged anti-VEGF treatment results in de-
velopment of geographic atrophy, leading to a disease state for which no treatment 
option exists, but the available data is still inconclusive [117-119]. VEGF is not only 
a major player in the development of CNV, but is also essential for the stability of 
the choriocapillaris [203]. And indeed, short-term effects of anti-VEGF treatment 
on the choriocapillaris in humans have been reported [228] and were also evident 
in monkey eyes treated with bevacizumab [150] or treated with either aflibercept 
or ranibizumab, as described in section 3.3.1 [2]. Since the choriocapillaris is al-
ready impaired in still healthy areas of wet AMD, as shown in section 3.1.1 [1], it is 
plausible that any further disturbances can be detrimental for the choriocapillaris. 
Current pre-clinical and clinical studies therefore also focus on other growth fac-
tors involved in CNV formation and stability, such as Ang-2 and pigment epitheli-
um-derived factor (PEDF). A new treatment approach is for instance the stabiliza-
tion of CNV-vessels (such as the above mentioned “labyrinth-like capillaries”) to 
prevent leakage as well as oedema formation and support the physiological func-
tion of the CNV as a “wound healing reaction” (Julien S, et al. IOVS 
2019;60:ARVO E-Abstract 366). This approach is supported by the finding of 
morphologically healthy photoreceptors and RPE cells which are nourished by un-
derlying morphologically functional CNV vessels, in the midst of retinal scar tis-
sue, as reported in section 3.1.1 [1]. 
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For the treatment of dry AMD and STGD1, several therapy approaches are under 
clinical investigation, but none are close to market maturity yet. In a further pro-
ject, which is not presented in this thesis, my colleagues and I investigate a sub-
stance called soraprazan (IUPAC name: (7R,8R,9R)-7-(2-methoxyethoxy)-2,3-
dimethyl-9-phenyl-7,8,9,10-tetrahydroimidazo[1,2-h][1,7]naphthyridin-8-ol; also 
called Remofuscin) that is capable to remove existing lipofuscin in vivo from the 
RPE of monkeys after oral treatment [229]. In this project, we aim to investigate 
whether a local application (intravitreal injection) of soraprazan can remove 
lipofuscin from the eyes of STGD1 model mice. Furthermore, toxicity, as well as 
morphologic and functional rescue are in the focus of this study. Since data acqui-
sition and evaluation is still ongoing, no peer-reviewed publication exists, but 
parts of the preliminary data were presented at the annual meeting of the Associa-
tion for Research in Vision and Ophthalmology (ARVO), the world’s largest vision 
research organisation (Taubitz T, et al. IOVS 2015;56:ARVO E-Abstract 4199; 
Taubitz T, et al. IOVS 2017;58:ARVO E-Abstract 257; Fang Y, et al. IOVS 
2017;58:ARVO E-Abstract 256). The data show that intravitreally applied sorapra-
zan can remove lipofuscin from the RPE of pigmented Abca4-/- mice at dosages 
that result in no toxic effects towards the retina and RPE as investigated by im-
munohistochemistry, electron microscopy and electroretinography. Lack of RPE 
toxicity was corroborated in cell culture experiments performed on primary RPE 
cells isolated from pigmented Abca4-/- mice. Data also point to a reduction of oxi-
dative stress markers and to a deceleration of the retinal degeneration after a sin-
gle intravitreal application of the compound in Abca4-/-.Rdh8-/- mice. Rescue ef-
fects were also evident in a light toxicity model where soraprazan reduced the reti-
nal degeneration of light-exposed pigmented Abca4-/- mice after a single intravi-
treal application compared to control. Meanwhile, in April 2019, a multi-national 
phase II study started to evaluate the safety and efficacy of oral soraprazan in pa-
tients with STGD1 (EudraCT number: 2018-001496-20). 
A benefit of the lipofuscin removal route for treatment is the lack of necessity for 
long-term or early start of treatment, especially for dry AMD patients: therapeutic 
approaches that rely on prevention of bisretinoid formation have to be applied ear-
ly in life before considerable amounts of lipofuscin have accumulated (e.g. gene 
therapy) or have to be used continuously (e.g. visual cycle inhibitors). This is a 
highly valuable route for patients with STGD1, since they experience high 
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lipofuscin amounts due to forced lipofuscin accumulation early in life. However, 
AMD is not caused by genetic factors, but merely the risk to develop AMD is de-
pendent on genetics, so approaches like gene therapy might only play a minor role 
in AMD therapy. Furthermore, since there is currently no way to predict whether 
an individual will develop AMD, preventive approaches like visual cycle inhibitors 
might be of limited practicality for AMD treatment. Indeed, a phase 2 study with 
the visual cycle modulator fenretinide failed to show a visual benefit after a 2-year-
treatment with 300 mg daily oral administration in dry AMD patients with geo-
graphic atrophy [230]. 
However, small molecules that are capable to eliminate lipofuscin, as for example 
the compound soraprazan [229] and cyclodextrins as described by Nociari et al. 
[231], have not only a high potential value in treatment of AMD, but also for 
STGD1: many parents of children affected from STGD1 are not aware they are car-
riers of ABCA4 mutations and that their children might inherit a blinding disease. 
Therefore, many patients are at the earliest diagnosed when they are already expe-
riencing the first signs of vision loss, which rules out any preventive treatment. 
These patients might benefit from an immediate reduction of their lipofuscin load, 
decelerating progression of retinal degeneration. In a subsequent step, other cur-
rently investigated treatment options that prevent future lipofuscin accumulation 
could be applied as a long-term remedy.  
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